Euthyroid heterogeneous thyroid ultrasound findings
A heterogeneous thyroid on ultrasound with a normal TSH is most often managed with clinical correlation and ultrasound-based risk stratification of any discrete thyroid nodules. Routine thyroid hormone suppression for thyroid nodules is not recommended in iodine-sufficient populations. [1]
Initial assessment
Key assessment elements include thyroid symptom review and careful ultrasound reassessment to determine whether any focal thyroid nodules are present rather than a purely diffuse heterogeneous pattern. [1]
- Repeat thyroid function testing is recommended when clinical symptoms suggest thyroid dysfunction or when initial testing may be unreliable (for example, assay interference). [2]
- Additional thyroid laboratory evaluation for autoimmune thyroid disease is considered when ultrasound heterogeneity suggests thyroiditis, because TSH can remain normal early in autoimmune disease. [2]
Ultrasound risk stratification for discrete nodules
Management is guided by the sonographic pattern and size of each discrete nodule, using the ATA ultrasound risk categories. [1]
- High suspicion patterns are managed with FNA based on established size/feature criteria and shorter follow-up intervals. [1]
- Intermediate suspicion patterns are managed with consideration of FNA at lower size thresholds than low-suspicion nodules. [1]
- Very low suspicion patterns have very low malignancy risk, and surveillance without FNA can be appropriate for many nodules. [1]
Fine-needle aspiration indications
FNA is not performed for a purely heterogeneous gland without a discrete nodule meeting ultrasound criteria. [1]
- FNA is performed for nodules that meet ATA size and sonographic-feature thresholds at baseline or on follow-up imaging. [1]
Follow-up ultrasound strategy when FNA is not performed
Sonographic follow-up is determined by the nodule’s ATA risk pattern when a nodule does not meet FNA criteria at initial imaging. [1]
- High suspicion pattern: repeat ultrasound in 6–12 months. [1]
- Low to intermediate suspicion pattern: consider repeat ultrasound at 12–24 months. [1]
- Very low suspicion pattern (including spongiform nodules and pure cysts): routine follow-up is not required for nodules ≤1 cm. [1]
- Very low suspicion pattern (>1 cm) including spongiform nodules and pure cysts: if ultrasound is repeated, the interval should be at least 24 months. [1]
Treatment role for euthyroid patients
Thyroid hormone suppression therapy for benign thyroid nodules is not recommended in iodine-sufficient populations. [1]
- Adequate iodine intake is recommended for adults with benign thyroid nodules. [1]
Clinical triggers for escalation
Escalation is indicated when ultrasound surveillance identifies new suspicious features or when growth prompts reassessment of malignancy risk. [1]
- Repeat FNA is prompted by development of new suspicious ultrasound features, not solely by growth. [1]
Common pitfalls to avoid
Over-reliance on “heterogeneous” gland description without identifying or documenting discrete nodules leads to misapplied management. [1]
- FNA and surveillance decisions should be tied to ATA ultrasound risk patterns and nodule size criteria rather than nodule growth alone. [1]
Goals of management
The goal is malignancy risk stratification of discrete nodules using ultrasound characteristics while avoiding unnecessary thyroid hormone suppression and unnecessary biopsies in euthyroid, low-risk scenarios. [1]